ITGA4
Integrin alpha-4
As of the edition of 20 October 2026, ITGA4 (integrin alpha-4, UniProt P13612) has 6 drugs tested at it and 7 companies on the list, 5 on route A and 2 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P13612
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 7
- Disease areas
- Digestive system; Immune system; Nervous system; Cancer; Infections; Urinary and reproductive; Blood and lymph; Skin and connective tissue
- Registered trials of its drugs
- 206
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 2 |
| Went quiet | 2 |
| Stopped | 2 |
| Total | 6 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Vedolizumab | Marketed | Phase 4 | Ended 2026 |
| Natalizumab | Marketed | Phase 4 | Ended 2016 |
| Abrilumab | Went quiet | Phase 2 | none listed |
| Firategrast | Went quiet | Phase 2 | none listed |
| UCB-1184197 | Stopped | Phase 2 | none listed |
| ATL1102 | Stopped | Phase 2 | none listed |
6 of 6 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 5 |
| Route B | 2 |
| Total on the list | 7 |
| Company | Route |
|---|---|
| Takeda | Route B |
| Biogen | Route B |
| AstraZeneca | Route A |
The other 4 companies at ITGA4
In the product7 companies in all; 4 are not named here, and no score is.
See the 7 companies at ITGA4, ranked, with the facts behind eachRequest access. Nothing is shown until you do.